N-苄基-4-(2-(苄基氨基)乙基)苯胺 | 344466-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苄基-4-(2-(苄基氨基)乙基)苯胺
• 英文名称: N-benzyl-4-[2-(benzylamino)ethyl]aniline
• CAS: 344466-47-3
• 化学式: C₂₂H₂₄N₂
• 分子量: 316.446
• InChiKey: XDBKHZDRFOGVMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  481.7±33.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-苄基-4-(2-(苄基氨基)乙基)苯胺 在 正丁基锂 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 生成 milveterol
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072
• 作为产物：
  描述：

  N-(4-(2-(benzylideneamino)ethyl)phenyl)-1-phenylmethanimine 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-苄基-4-(2-(苄基氨基)乙基)苯胺
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072

文献信息

• CHEMICAL PROCESS AND NEW CRYSTALLINE FORM
  申请人：CAINE Darren Michael

  公开号：US20100063157A1

  公开（公告）日：2010-03-11

  The present invention relates to the preparation of a β 2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I) in particular a crystalline monohydrochloride salt. The invention also relates to a new crystalline form (polymorph) of the monohydrochloride salt of compound (Ia) and a process for preparing it.

  本发明涉及制备β2肾上腺素受体激动剂的晶体盐形式。特别地，本发明涉及制备化合物(I)的晶体盐，特别是晶体单盐酸盐。本发明还涉及化合物(Ia)的单盐酸盐的一种新的晶体形态（多晶形式）及其制备方法。
• US7846973B2
  申请人：——

  公开号：US7846973B2

  公开（公告）日：2010-12-07
• A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD
  作者：John R. Jacobsen、Seok Ki Choi、Jesse Combs、Eric J.L. Fournier、Uwe Klein、Juergen W. Pfeiffer、G. Roger Thomas、Cecile Yu、Edmund J. Moran

  DOI：10.1016/j.bmcl.2011.11.072

  日期：2012.1

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.